prevention

systematic review meta-analysis network meta-analysis

Select atrial fibrillationdiabetes type 2impaired fasting glucose post strokepostthrombotic syndrome All type of patientprimary preventionuncoded clinical condition ***       alpha-glucosidase inhibitorangiotensin receptor blockerangiotensin-converting enzyme inhibitorsanti-obesity agentsantidiabetic drugsCEIdrugs + lifestyle modificationgemfibrozilglitazonesherbal preparationinhibition of renin-angiotensin systeminsulinlifestyle modificationn-3 fatty acid supplementplasma homocysteine lowering interventionstatinsvenous compression atorvastatinpravastatinrosuvastatinenalaprillisinoprilramiprilirbesartanlosartanvalsartancandesartandietfolic acidgemfibrozilglargineglipizidemetforminnateglinideolmesartanorlistatrosiglitazonetroglitazonevoglibose vs beta-blockersvs placebovs placebo or controlvs folic acid, vit B12 and vit B6      

Filter

Group by Group by... nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition MA  in first nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in second nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in third	Description Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Results Global trial result Main results All results All result tag NCT results	Diabetes (56)cardiovascular events (14)All cause death (13)Cardiovascular death (12)atrial fibrillation (11)atrial fibrillation recurrence (9)normoglycemia (9)stroke (fatal and non fatal) (8)myocardial infarction (fatal and non fatal) (7)hospitalisation for heart failure (7)mild to-severe postthrombotic syndrome (5)mild-to-moderate postthrombotic syndrome (4)severe postthrombotic syndrome (4)cardiovascular death, MI, stroke (3)more than one AF recurrence (1)Vascular events (1)Vascular death (1)Non fatal MI (1) Options Numeric bar chart forest plot medians
Trial	Studied trt	Control trt	patients	tags	ROB	Trial result	Diabetes	cardiovascular events
atrial fibrillation
atorvastatin
Ozaydin, 2006	atorvastatin	control			Exploratory	suggesting
Almroth, 2009	atorvastatin	placebo			Low risk of bias	suggesting
MIRACL (sub-group) (Schwartz), 2004	atorvastatin	placebo			Low risk of bias	suggesting
Dernellis, 2006	atorvastatin	placebo			Exploratory	suggesting
ARMYDA-3 (AF ancillary study), 2006	atorvastatin	placebo				suggesting
Chello, 2006	atorvastatin	placebo			Low risk of bias	negative
MIRACL (AF ancillary study), 2001	atorvastatin	placebo			Low risk of bias	negative
candesartan
CHARM (AF ancillary study), 2005	candesartan	placebo				suggesting
CAPRAF (Tveit), 2007      NCT	candesartan	placebo			Low risk of bias	-
enalapril
Ueng, 2003	enalapril	control				suggesting
SOLVD (AF ancillary study), 2003	enalapril	placebo				suggesting
gemfibrozil
VA HIT (AF ancillary study), 1999	gemfibrozil	placebo			Low risk of bias	negative
irbesartan
Madrid, 2002	irbesartan	control				suggesting
ACTIVE I, 2009    NCT	irbesartan	placebo			Low risk of bias	suggesting
lisinopril
Van den Burg, 1995	lisinopril	placebo			Low risk of bias	negative
GISSI-3 (AF ancillary study), 2003	lisinopril	placebo				negative
losartan
LIFE (AF ancillary study), 2005	losartan	atenolol				suggesting
pravastatin
Tveit, 2004	pravastatin	control			Exploratory	negative
rosuvastatin
GISSI HF (subgroup and ancillary study), 2009    NCT	rosuvastatin	placebo			Low risk of bias	negative
valsartan
Val-HeFT (AF ancillary study), 2003	valsartan	placebo				suggesting
GISSI-AF (Disertori), 2009      NCT	valsartan	placebo			Low risk of bias	negative
diabetes type 2
diet
Liao, 2002	AHA 2 diet	AHA 1 diet			Exploratory	negative
glargine
GRACE - ORIGIN (glargine), 2012	insulin glargine	placebo			Risk of bias	-
glipizide
Eriksson, 2006	glipizide	placebo			Low risk of bias	negative
metformin
Jarret, 1979	lifestyle modification + metformin	control			Exploratory	negative
IDDP (Ramachandran), 2006	lifestyle modification + metformin	control			Risk of bias	negative
James, 2005	metformin	control				-
Rodriguez-Moctezuma, 2004	metformin	placebo				negative
Sirtori, 1984	metformin	placebo				-
Srinivasan, 2006	metformin	placebo				-
US-DPP (metformin) (Knowler), 2002	metformin	placebo			Low risk of bias	negative
EDIT (Holman), 2003	metformin	placebo				-
Stakos, 2005	metformin	placebo				-
Li, 1999	metformin	placebo			Low risk of bias	negative
Sturrock, 2002	metformin	placebo				-
Tang, 2006	metformin	placebo				-
Vitale, 2005	metformin	placebo				-
Baillargeon, 2004	metformin	placebo				-
Bridger, 2006	metformin	placebo				-
Charles, 1998	metformin	placebo				negative
Charles, 2000	metformin	placebo				-
Choux, 2003	metformin	placebo				-
Crave, 1995	metformin	placebo				-
Fleming, 2002	metformin	placebo				-
Freemark, 2001	metformin	placebo				-
Gambineri, 2004	metformin	placebo				-
Giugliano, 1993	metformin	placebo				-
Hoeger, 2004	metformin	placebo				-
Kay, 2001	metformin	placebo				-
Kelly, 2002	metformin	placebo				-
Kocak, 2002	metformin	placebo				-
Lehtovirta, 2001	metformin	placebo				negative
Moghetti, 2000	metformin	placebo				-
Morel, 1999	metformin	placebo				-
Ng, 2001	metformin	placebo				-
Orchard, 2005	metformin	placebo				suggesting
Pasquali, 2000	metformin	placebo				-
Rodriguez, 2004	metformin	placebo				-
CANOE, 2010      NCT	rosiglitazone and metformin	placebo			Low risk of bias	suggesting
nateglinide
NAVIGATOR nateglinide, 2010    NCT	nateglinide	placebo			Low risk of bias	negative
orlistat
Heymsfield, 2000	orlistat	placebo			Low risk of bias	negative
XENDOS (Chiasson), 2002	orlistat	placebo			Low risk of bias	negative
ramipril
DREAM ramipril, 2006        NCT	ramipril	placebo			Low risk of bias	negative
rosiglitazone
DREAM rosiglitazone, 2006      NCT	rosiglitazone	placebo			Low risk of bias	suggesting
troglitazone
TRIPOD (Buchanan), 2002	troglitazone	placebo			Low risk of bias	-
US DDP troglitazone (Knowler), 2005	troglitazone	placebo			Low risk of bias	-
valsartan
NAVIGATOR valsartan, 2010        NCT	valsartan	placebo			Low risk of bias	suggesting
voglibose
Voglibose Ph-3, 2009	voglibose	placebo			Low risk of bias	suggesting
impaired fasting glucose
glargine
GRACE - ORIGIN (glargine), 2012	insulin glargine	placebo			Risk of bias	-
metformin
US-DPP (metformin) (Knowler), 2002	metformin	placebo			Low risk of bias	negative
CANOE, 2010      NCT	rosiglitazone and metformin	placebo			Low risk of bias	suggesting
nateglinide
NAVIGATOR nateglinide, 2010    NCT	nateglinide	placebo			Low risk of bias	negative
ramipril
DREAM ramipril, 2006        NCT	ramipril	placebo			Low risk of bias	negative
rosiglitazone
DREAM rosiglitazone, 2006      NCT	rosiglitazone	placebo			Low risk of bias	suggesting
valsartan
NAVIGATOR valsartan, 2010        NCT	valsartan	placebo			Low risk of bias	suggesting
voglibose
Voglibose Ph-3, 2009	voglibose	placebo			Low risk of bias	suggesting
post stroke
folic acid
VITATOPS, 2010    NCT	folic acid, vit B12 and vit B6	placebo			Low risk of bias	suggesting
VISP (Toole), 2004	high dose - folic acid, vit B12 and vit B6	low dose - folic acid, vit B12 and vit B6			Low risk of bias	negative